Accelerating & De-Risking Drug R&D

Development-aware mAb engineering across affinity, aggregation, paratope liabilities, formulation risk, expression, and scalable progression.

VHH-specific design and screening for cryptic epitope access, hydrophobic patch risk, renal clearance, half-life extension, and humanization.

Coordinate binding geometry, affinity asymmetry, chain pairing, assembly, bridging efficiency, expression, and safety risk across multi-target formats.

Integrate antibody binding, internalization, linker stability, payload hydrophobicity, conjugation strategy, DAR, and off-target payload risk.

Assess fusion-partner stability, linker clipping, steric accessibility, retained function, expression, and target-mediated disposition across complex biologics.

Rank binding, PK/PD, aggregation, viscosity, hydrophobicity, solubility, expression, immunogenicity, CMC, and class-specific progression risk.

Prioritize macrocycle topology, conformational stability, permeability tension, cyclization strategy, and target-interface fit before synthesis expansion.

Explore staple placement and constrained geometry under helical stability, intracellular PPI engagement, solubility, and hemolysis constraints.

Balance uptake, endosomal escape, hemolysis, mast-cell risk, exposure, and delivery constraints to rank CPP vectors.

Improve peptide series by ranking solubility, aggregation, hydrophobicity, hemolysis, synthesis readiness, and functional motif risk.

Coordinate targeting peptide affinity, linker stability, payload or radionuclide behavior, stoichiometry, exposure, and off-target payload risk.